SynthesisNeurourology and urodynamics2023
Sacral neuromodulation in the management of chronic pelvic pain: A systematic review and meta-analysis.
Synthesis in Neurourology and urodynamics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- [Update of the S2k guideline on the diagnosis and treatment of interstitial cystitis/bladder pain syndrome (IC/BPS)].Urologie (Heidelberg, Germany) · 2026Guideline
- Clinical phenotypes and treatment patterns in men with chronic pelvic pain: a tertiary referral cohort.International urology and nephrology · 2026Article
- Sacral Nerve Modulation Alleviates Neuropathic Pelvic Pain Through Modulation of the Spinal Immune Microenvironment and Microglial Activation.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026Article
- Neuromodulation for Lower Urinary Tract Dysfunction: Mechanisms, Modalities, and Patient Selection.International urogynecology journal · 2026Review
- Pulsed radiofrequency of S2-4 nerve roots vs ganglion impar neurolysis for severe perineal cancer pain.Pain reports · 2026Article
- The pelvic floor: myth or hype?-a narrative review.Gynecology and pelvic medicine · 2026Review
- Advancing women's health: innovative applications of sacral neuromodulation in pelvic floor dysfunctions.Archives of gynecology and obstetrics · 2025Review
- Overcoming barriers to accessing sacral neuromodulation care in Canada Re: "Urologist-perceived barriers and perspectives on the underuse of sacral neuromodulation for overactive bladder in Canada" (Can Urol Assoc J 2023;17:E165-71).Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- Good long-term results of sacral neuromodulation for endometriosis related chronic pelvic pain.BMC women's health · 2025Article
- Article
- Clinical Comorbidities and Videourodynamic Characteristics of Dysfunctional Voiding in Women.Biomedicines · 2025Article
- Differential effects of low- and high-frequency sacral neuromodulation on urinary symptoms: high-frequency improves Qmax, low-frequency enhances bladder capacity.American journal of translational research · 2025Article
- Review
- Neuromodulation Techniques in Chronic Refractory Coccydynia: A Narrative Review.Pain and therapy · 2024Review
- Updates in pelvic neuromodulation: the role of pelvic neuromodulation in pelvic disorders.Frontiers in urology · 2024Review
- Dysmenorrhea, a Narrative Review of Therapeutic Options.Journal of pain research · 2024Review
- Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSacral neuromodulation (SNM) is a treatment approved for use in several conditions including refractory overactive bladder (OAB) and voiding dysfunction. Chronic pelvic pain (CPP) is a debilitating condition for which treatment is often challenging. SNM shows promising effect in patients with refractory CPP. However, there is a lack of clear evidence, especially in long-term outcomes. This systematic review will assess outcomes of SNM for treating CPP.
methodsA systematic search of MEDLINE, Embase, Cochrane Central and clinical trial databases was completed from database inception until January 14, 2022. Studies using original data investigating SNM in an adult population with CPP which recorded pre and posttreatment pain scores were selected. Primary outcome was numerical change in pain score. Secondary outcomes were quality of life assessment and change in medication use and all-time complications of SNM. Risk of bias was assessed using the Newcastle Ottawa Tool for cohort studies.
resultsTwenty-six of 1026 identified articles were selected evaluating 853 patients with CPP. The implantation rate after test-phase success was 64.3%. Significant improvement of pain scores was reported in 13 studies; three studies reported no significant change. WMD in pain scores on a 10-point scale was -4.64 (95% confidence interval [CI] = -5.32 to -3.95, p < 0.00001) across 20 studies which were quantitatively synthesized: effects were maintained at long-term follow-up. Mean follow-up was 42.5 months (0-59). Quality of life was measured by RAND SF-36 and EQ-5D questionnaires and all studies reported improvement in quality of life. One hundred and eighty-nine complications were reported in 1555 patients (Clavien-Dindo Grade I-IIIb). Risk of bias ranged from low to high risk. Studies were case series and bias stemmed from selection bias and loss to follow-up.
conclusionSacral Neuromodulation is a reasonably effective treatment of Chronic Pelvic Pain and significantly reduces pain and increases patients' quality of life with immediate to long-term effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.